Description:

VEGF-AS Administration Form for Protocol 043 NCT00310128 Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FFA090C4-D408-6439-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FFA090C4-D408-6439-E034-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 1/9/15
  3. 6/16/15
Uploaded on:

June 16, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

VEGF-AS Administration Form for Protocol 043 NCT00310128

No Instruction available.

  1. StudyEvent: VEGF-AS Administration Form for Protocol 043
    1. No Instruction available.
Administration Form
Has the patient received a dose escalation or dose reduction of this agent during this administration
Did the patient experience any adverse events
Dose assigned
have all adverse events been reported on the Adverse Event Form